化学
细胞毒性
细胞毒性T细胞
体内
结合
免疫疗法
癌症研究
免疫系统
肿瘤细胞
体外
药理学
肿瘤微环境
细胞
细胞培养
癌症免疫疗法
细胞生长
作用机理
T细胞
毒素
作者
Bi-Chun Chen,Jinyu Bai,Huaihuai Shi,Hao Rui,Jiaxin Liang,Hui Tian,Guiyang Yao,Ximing Shao,Hongchang Li,Ruibing Wang,Wu Su,Lijing Fang
标识
DOI:10.1021/acs.jmedchem.5c02262
摘要
Due to the heterogeneity of tumors and the complex regulatory mechanisms governing PD-L1 expression, immunotherapy that employs PD-1/PD-L1 inhibitors has shown limited efficacy and relatively low response rates. In this work, we propose that a Degrader-Drug Conjugate (DDC), comprising a PD-L1 degrader linked to a cytotoxic agent, may enhance antitumor efficacy by synergizing immune activation with direct cell killing. Mechanistically, the DDC promotes PD-L1 degradation via the endosomal-lysosomal pathway to alleviate immunosuppression, while simultaneously releasing a cytotoxic agent inside tumor cells to induce apoptosis. Among the two DDCs developed in this study, BMS-RGD-MMAE exhibits superior toxin release efficacy, enhanced plasma stability, and increased cytotoxicity compared to BMS-RGD-DXd. Moreover, BMS-RGD-MMAE significantly inhibits tumor growth in vivo through synergistic PD-L1 degradation and toxin-mediated cell death, underscoring its substantial potential for application in tumor immunochemotherapy. Overall, this DDC platform provides new opportunities for the advancement of antitumor therapeutics.
科研通智能强力驱动
Strongly Powered by AbleSci AI